In¯ammatory breast carcinoma (IBC) is characterized by¯orid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a humanscid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2K d -E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/a, b-catenin axis which mediates tumor cell ± tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the eects of palpation on MARY-X with the eects of palpation on a derived dominant-negative E-cadherin mutant (H-2K d -E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24 met ) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10?30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10 ± 100-fold (P50.001) only in MARY-X. The mechanism of this eect was through an immediate post-palpation release of circulating tumor emboli detected 2 ± 3 min after palpation (P50.01) by human cytokeratin 19 RT ± PCR of extracted RNA from 300 ml of murine blood. Although circulating human tumor cell ± derived growth factors (IGF-I, IGF-II, TGFa and TGF-b) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P40.1). Our ®ndings support the cooperative role of E-cadherin and sialyl-Lewis X/Ade®cient MUC1 in the passive dissemination of tumor emboli in IBC.
Introduction
Metastasis is considered to be an active biological process involving complex interactions between the cancer cell, the extracellular matrix, the vasculature, the immune system, and the target organ (Liotta et al., 1991) . Experimental studies over the past two decades have de®ned some of the eector molecules involved in this complex process . Metastasis has been generally regarded as a late event in tumor progression allowing the opportunity for curative therapeutic intervention during a time when the primary cancer remains organ-con®ned (Silverstein, 1997) . Still some cancers seem to escape organ con®nement very early in their natural history and confound attempts at both successful screening and therapy. An example of the latter type of cancer is in¯ammatory breast carcinoma (IBC) which presents with¯orid lymphovascular invasion (LVI) of tumor emboli and micrometastasis at its onset (Levine et al., 1985) .
We have partially characterized the molecular basis of IBC using a novel human-scid murine model (MARY-X) which exhibits¯orid LVI and lung metastases (Alpaugh et al., 1999; Tomlinson et al., 2001) . In these studies, we have demonstrated that MUC1 and E-cadherin are both overexpressed and that it is, in particular, the intact and overexpressed Ecadherin/a,b-catenin axis that is required for the formation of tumoral spheroids in vitro and lymphovascular emboli in vivo (Tomlinson et al., 2001) . MARY-X consists of a con¯uence of tumor nodules growing in a host mesenchyme in the central part of the xenograft. The tumor nodules evolve into tumor emboli within lymphovascular spaces at the tumor's periphery (Alpaugh et al., 1999) . This pattern is observed irrespective of the size of the primary tumor. We have observed this histology in tumors ranging from 0.5 to 2.0 cm in diameter. The degree of vascularization and permeation of the primary tumor by lymphoreticular vessels is signi®cant but no greater that that observed in non-in¯ammatory tumoral xenografts, e.g., C8161 and MDA-MB-231. What is unique about MARY-X is that its lymphovascular spaces (lymphoreticular vessels) are ®lled with tumor emboli. MARY-X is not an artefactual model. The model was derived from a case of human in¯ammatory breast cancer and grows as a transplantable xenograft in nude/scid mice where it has maintained a stable in¯ammatory breast carcinoma phenotype of lymphovascular invasion. All gene products analysed to date, e.g. E-cadherin, MUC1, that are expressed in MARY-X are also expressed in actual cases of human in¯ammatory breast cancer (Alpaugh et al., 1999; Tomlinson et al., 2001; Kleer et al., 2001) . The rapidity of progression of this particular cancer raises the possibility that perhaps IBC short-circuits some of the classic active steps of metastatic progression by virtue of its expression of the particular eector molecules which de®ne its phenotype. We decided to speci®cally address this hypothesis in the present study.
Results
The MARY-X phenotype ( Figure 1 ) exhibited¯orid lymphovascular tumor emboli or lymphovascular invasion (LVI) and when one observed these emboli closely, one noted compact tumor emboli retracted away from the surrounding endothelial cell layer lining the lymphovascular space ( Figure 1a ). These emboli corresponded to compact spheroids in suspension culture (Figure 1b) . Immunocytochemical studies using antibodies to E-cadherin indicated that the cells of the MARY-X spheroid exhibited strong surface E-cadherin immunoreactivity ( Figure 1c) . All of the cells of the spheroids (surface cells and internal cells) demonstrated this E-cadherin membrane immunoreactivity. The intensity of the staining was heterogeneous but that would be expected in any immunocytochemical preparation. Spheroids were successfully transfected with the dominant negative E-cadherin mutant (H-2K d -Ecad) using the disadherence/transfection/readherence strategy enumerated in the Materials and methods section. By immuno¯uorescence studies, the spheroids uniformly expressed this construct at 72 h following transfection ( Figure 1d) ; full disadherence occurred at 96 hours following transfection (Figure 1e ). When the spheroids that received the dominant negative Ecadherin mutant (H-2K d -E-cad) were re-injected into scid mice, they no longer exhibited their characteristic phenotype of¯orid LVI and instead exhibited a phenotype of single cell in®ltration (Figure 1f) . Spheroids receiving the dominant negative E-cadherin control construct (H-2K d -E-cadD25) in which the catenin binding site had been destroyed by a 25 amino acid deletion in the cytoplasmic domain which, in essence, cancelled the dominant-negative eect, did not undergo disadherence in vitro and maintained the characteristic IBC phenotype of¯orid LVI when reinjected into scid mice.
In contrast to the strong homotypic tumor cell adhesion, we did not observe tumor cell heterotypic adhesion to endothelial cells either in vitro or in vivo (Figure 2 ). Although the MARY-X spheroids overexpressed MUC1 (Figure 2A ), they also exhibited markedly decreased sialyl-Lewis X/A epitopes (the natural ligands for endothelial selectins) by Western blot studies (Figure 2a) . These results were mirrored in immunocytochemical studies. Although the MARY-X spheroids ( Figure 2b ) overexpressed cell-surface MUC1 (Figure 2c ), they again exhibited markedly decreased cell surface sialyl-Lewis X/A residues (Figure 2d ). These results were also observed in actual cases of IBC. The lymphovascular tumor emboli in 25 out of 25 cases of IBC exhibited strong MUC1 immunoreactivity ( Figure 2e ) but weak to absent sialyl-Lewis X/A immunoreactivity ( Figure 2f ). Actual cases of IBC also exhibited at the light microscopic level compact tumor emboli which retracted from the surrounding endothelial cell layer lining the lymphovascular space ( Figure  2g ) just as had been observed in the lymphovascular emboli of MARY-X (Figure 1a) . The MARY-X spheroids only weakly and non-speci®cally bound to an underlying monolayer of HUVECs (Figure 2h ). This attachment was not enhanced by pretreatment of the HUVECs monolayer with 200 U/ml of TNF-a, a cytokine which increased E-selectin 20 ± 50-fold (data not shown). Other cell lines examined, e.g. showed signi®cant attachment to HUVECs which was considerably enhanced by HUVECs' TNF-a pretreatment (Figure 2h ). Dissociated MARY-X spheroids that had received the dominant negative E-cadherin mutant (H-2K d -E-cad), like their parental MARY-X spheroids, only weakly and non-speci®cally bound to HUVECs (Figure 2h ). This experimental observation correlates with the appearance of the lymphovascular emboli in human cases of in¯ammatory breast cancer where the embolus appears retracted away from the endothelial-lined vessel (Figure 2g ). Our observations concerning the lack of the spheroids of MARY-X attaching to HUVECs is related to the hypothesis that the lack of sialyl-Lewis X/A carbohydrate ligand-binding epitopes on MUC1 of MARY-X causes the tumor cells not to bind to endothelial E-selectin. The compactness of the spheroids due to strong E-cadherin homotypic binding interactions and the tumor embolus' aversion to endothelial cells due to markedly decreased sialylLewis X/A ± E-selectin binding epitopes suggested to us that this speci®c IBC phenotype might foster passive metastatic dissemination. We decided to test this latter hypothesis with a series of palpation experiments.
Palpation resulted in a similar increase in intratumoral pressure in all of the xenograft groups. During palpation, intratumoral pressures increased by approximately 200% (10?30 mmHg) in all xenograft groups (Table 1) . Palpation per se (Figure 3 ) exerted no eects on tumor growth, size or histological characteristics of any of the primary xenografts but dramatically increased the numbers and sizes of pulmonary lymphovascular embolic metastases 10 ± 100-fold (P50.001) in MARY-X (Figure 3a ± c) . This eect was observed for both the¯ank as well as the mammary fat pad injections. Palpation did not induce metastasis in the non-metastatic xenografts (MCF-7, T47D) (P40.1) nor enhance metastasis in the lowly metastatic xenografts (MDA-MB-231, MDA-MB-468) (P40.1) nor increase metastasis in the highly metastatic xenografts (C8161, M24 met ) which metastasized as single cells but which did not manifest lymphovascular emboli (P40.1) (Figure 3d ). Palpation also did not induce or enhance metastasis in the MARY-X dominant negative E-cadherin mutant (H-2K
d -E-cad) nor in the COLO-201 or COLO-205 xenografts (data not shown).
The mechanism of the palpation-enhancement of pulmonary lymphovascular embolic metastases in native MARY-X was through an immediate postpalpation release of circulating tumor cells detected 2 ± 3 min after palpation (Figure 4 ) (P50.01) by human cytokeratin 19 RT ± PCR of extracted RNA from Results with MDA-MB-468-X were similar.
e Results with T47D-X were similar.
of any MDA-MB-231 (P40.1) or C8161 cells (P40.1) ( Figure 4c ). Palpation also did not result in any detectable circulating tumor cells in the MARY-X dominant negative E-cadherin mutant (H-2K
d -E-cad) ( Figure 4c ). Therefore the apparent cause of the palpation-induced increase in size and number of the pulmonary lymphovascular emboli in native MARY-X was the palpation-mediated release of increased numbers of MARY-X tumor cells into the circulation or passive metastasis. It should be recalled that MARY-X manifested an exaggerated degree of lymphovascular emboli formation or LVI in the primary tumor whereas the MARY-X dominant negative E-cadherin mutant (H-2K
d -E-cad), the highly metastasizing C8161 and the lowly-metastasizing MDA-MB-231 all did not. Palpation resulted in no detectable tumor cells being released into the circulation in either the MARY-X dominant negative Ecadherin mutant (H-2K d -E-cad), the MDA-MB-231 or the C8161 xenografts.
In both the non-palpated as well as palpated arms of the MARY-X experiments, the pulmonary lymphovascular emboli manifested a spectrum of histological manifestations ( Figure 5 ), all supporting the conclusion that the emboli were maintaining their homotypic compactness and their heterotypic aversion (Figure 5a ), sometimes as a result, wedging at bifurcation points (Figure 5b) , mechanically obstructing the pulmonary vasculature (Figure 5c ) or serving as a nidus for ®brin and platelet accumulation (Figure 5d ). In the palpated arm of the experiment, all of these manifestations were more frequent. Although circulating human tumor cell-derived growth factors (IGF-I, IGF-II, TGF-a and TGF-b) and angiogenic factors (VEGF and bFGF) in the pg to ng range were detected by ELISA in the murine serum of MARY-X, palpation of this xenograft did not further increase the circulating levels of these factors (P40.1) (Figure 6 ).
Discussion
Very little is known concerning the molecular mechanisms or the biology of IBC. This study presents the message that robust expression of an epithelial adherence molecule such as E-cadherin can strongly in¯uence the character of the metastatic embolus. It is proposed that strong E-cadherin expression and weak expression of adhesive receptors for tumor cellendothelium attachment generates metastases in the form of compact spheroids. Further, it is suggested that metastatic localization in this situation is a result of passive entrapment in ®ne blood vessels rather than active adhesive recruitment of tumor emboli to the luminal surface of the vascular endothelium. This is important because so much of the recent interest has centered on active tumor embolus-endothelium adhesion during the arrest phase of the metastatic cascade. It is also interesting that a tumoral xenograft, MARY-X, that expresses high levels of E-cadherin is nevertheless highly metastatic because in other tumor lines, E-cadherin expression can prevent metastasis. This system is proposed as a model for in¯ammatory breast carcinoma. It is important to emphasize that our model is one of spontaneous metastasis. We have used the term passive metastasis to indicate a particular type of spontaneous metastasis ± one which can be stimulated by passive means, i.e. palpation.
Other investigators have begun to study the higher level genetic determinants of IBC and have identi®ed two genes: LIBC (lost in IBC) and RhoC GTPase (Van Golen et al., 1999 . The expression of the ®rst gene was lost and the expression of the second gene was increased in an in¯ammatory breast carcinoma cell line and in archival human in¯ammatory breast cancers. We are currently investigating the expression of these two genes in MARY-X. Presently, no one knows how many genetic changes determine the in¯ammatory breast cancer phenotype ± whether there are few or many. Clearly a number of dierent molecules are involved.
Our results suggest that in IBC, passive dissemination of tumor emboli, what we have termed passive metastasis, occurs and results in the ease of metastatic dissemination. There are two main kinds of metastasis: spontaneous and experimental (hematogenous). Spontaneous metastasis refers to both the autochthonous situation in humans as well as experimental animal models where the primary tumor is implanted locally and then spontaneously metastasizes to distant sites. Experimental (hematogenous) metastasis, on the other hand, is when tumor cells are directly injected into the circulation. In our paper we are de®ning passive metastasis as a type of spontaneous metastasis which occurs following minimal perturbation such as palpation. Our results oer an explanation of why IBC escapes organ-con®nement very early in its natural history. Our results suggest that IBC short-circuits some of the classic active steps of metastatic progression that other cancers must of necessity progress through. In IBC the formation of local lymphovascular tumor emboli is sucient for metastatic dissemination. Other recent studies have similarly re-examined and challenged the canonical steps of the metastatic process and found, for example, that classic extravasation can be short-circuited by simple proliferation of endothelial-attached tumor cells at the metastatic site (AlMehdi et al., 2000) .
Our results not only show that passive dissemination of tumor emboli occurs in IBC but also elucidate the eector molecules responsible for the tumor embolic formation in the ®rst place. Interestingly, the same eector molecules, E-cadherin and sialyl-Lewis X/A de®cient MUC1 which account for the compact tumor embolus sitting in the center of the lymphovascular space also account for its passivity and eciency of metastatic dissemination. We appreciate that it would be dicult to understand how the large tumor emboli of MARY-X establish themselves in the lumens of vessels in the ®rst place. Our preliminary studies have suggested that the tumor nodules do not invade the lymphovascular spaces but rather that the lymphovascular structures form around the tumor nodules. We are addressing this latter hypothesis presently in another study.
An overexpressed E-cadherin axis causes compactness of the tumor embolus analogous to the embryonic blastocyst and results in eciency of implantation in both settings. Interestingly the embryonic blastocyst also overexpresses E-cadherin (Gumbiner, 1996; Yap et al., 1997) . Numerous previous studies have demonstrated that hematogenous tumor cell clumps are very ecient at metastatic dissemination and implantation (Liotta et al., 1976) . Furthermore tumor cell clumps are hypoxic in their centers and resistant to the therapeutic eects of radiation therapy and chemotherapy (Moore et al., 1992) . Predictably abolishing the Ecadherin-mediated homotypic adhesion with a dominant negative E-cadherin mutant approach signi®cantly altered the tumor embolic phenotype of MARY-X and resulted in the abolishment of both local lymphovascular tumor emboli and passive metastasis. We have in vitro evidence that many but not all of the cells of the disadhered spheroids undergo apoptosis as measured by a TUNEL assay. This apoptosis seems to belong to the category of anoikis, the details of which are the subject of another study. The dissociation preceeds the apoptosis rather than the other way around. We know this because we can also fully dissociate the spheroids by growing them in Ca 2+ free medium for 30 min. The dissociated cells, after 6 h, undergo apoptosis. However if we add Ca 2+ back before 6 h have elapsed, the spheroids reform and apoptosis does not occur. Therefore the apoptosis follows rather than preceeds dissociation.
The lack of sialyl-Lewis X/A on MUC1 on MARY-X accounts for the lack of appreciable tumor cellendothelial cell attachment both in vitro and in vivo which in turn facilitates passive metastasis. One of the early steps of active metastasis involves the attachment of tumor cells to the endothelium. More speci®cally this attachment or adhesion process is thought to involve interactions between endothelial cell E-selectin and its glycoconjugate ligands sialyl Lewis X (sLeX) and sialyl Lewis A (sLeA) on tumor cells (Kansas, 1996) . Therefore our demonstration of the lack of sialyl-Lewis X/A on MUC1 in MARY-X is signi®cant in promoting passive not active metastasis. Some of the other non-in¯ammatory xenografts, e.g. COLO-205 and COLO-201 which express sialyl-Lewis X/A epitopes on MUC-1, attach to endothelial cell E- selectin in vitro and presumably in vivo, do not manifest passive metastasis. Other non-metastatic, low ± metastatic and high metastatic xenografts which do not exhibit lymphovascular invasion also do not manifest passive metastasis.
When one looks at the two eector molecules responsible for the appearance of the compact tumor embolus sitting in the center of the lymphovascular space, one observes a possible synergy or cooperativity between E-cadherin and the sialyl-Lewis X/A de®cient MUC1. This is based on two lines of reasoning. The ®rst is that the lack of heterotypic adhesion between tumor cell and endothelial cell promotes the natural homotypic adhesion between tumor cells in the tumor embolus and indirectly contributes to the compactness of the embolus. The second is that if the MUC1 on the IBC tumor embolus contained sialyl-Lewis X/A residues, it would be anticipated that the strong electrostatic repulsions of negative charges known to be present on these residues would likely disrupt or weaken the E-cadherin homodimers responsible for the natural homotypic adhesion between tumor cells in the tumor embolus. We do not yet understand the mechanism behind the decreased sialyl-Lewis X/A on MUC-1 in MARY-X and IBC. Conceivably either MARY-X or IBC lacks the requisite glycosyltransferases (fucosyltransferases) responsible for adding sialyl-Lewis X/A on MUC-1 or the overexpressed MUC-1 overwhelms the endogenous levels of glycosyltransferases (fucosyltransferases) which are present. We are planning future studies to address the mechanisms involved.
In comparing passive metastasis (palpation) in the dierent xenografts, it was important initially to demonstrate that palpation exerted similar eects on intratumoral pressure. It was not a foregone conclusion that this would be the case as the intrinsic interstitial tumoral pressure is thought to vary considerably among dierent tumors depending on their state of hypoxia, cell density, associated extracellular matrix, etc. (Rutz, 1999) . The fact that the eects of palpation were equally transduced into the dierent xenografts allowed us to compare the eects of this pressure transduction among the xenografts without having to deal with intraluminal pressure as an added variable.
Palpation was eective at enhancing embolic dissemination but not eective at increasing intravasation and subsequent dissemination (since if this were the case both the C8161 and the MDA-MB-231 would have showed increased tumor cells in the circulation and increased pulmonary metastasis); or dissemination of single tumor cells (since if this were the case, the C8161 would have showed increased metastasis); or extravasation (since if this were the case, RT ± PCR would not have demonstrated an increased number of circulating tumor cells of MARY-X); or tumor growth (since if this were the case, palpated xenografts would be larger in size). These observations are also important in distinguishing the concept of passive metastasis from active metastasis.
Since palpation could have also resulted, not in passive metastasis, but in the release of circulating growth and angiogenic factors which could have accounted for the apparent increase in number and size of pulmonary lymphovascular emboli in MARY-X, it was important to demonstrate that palpation did not result in an increase in circulating factors such as (IGF-I, IGF-II, TGF-a and TGF-b) and angiogenic factors (VEGF and bFGF) which could have directly stimulated growth of the metastatic colony or angiogenesis at the metastatic site. We are therefore hypothesizing that trauma or palpation of tumors that have pre-existing lymphovascular emboli at the primary tumoral site promotes embolic metastasis. We are not implying that trauma or palpation abets metastasis in general, just in tumors with a propensity for passive metastasis. Since previous studies have shown that tumor emboli are more ecient at forming metastases than single cells (Liotta et al., 1976) and that hematogenous metastases originate from the proliferation of attached intravascular tumor cells rather than extravasated ones (Al-Mehdi et al., 2000) , reducing passive metastasis from lymphovascular emboli by preventive measures is highly desirable.
Both past experimental and clinical studies have implicated palpation as a passive metastasis-promoting maneuver (Liotta et al., 1976; Nishizaki et al., 1990; Mori et al., 1996) . The signi®cance of circulating tumor cells by RT ± PCR detection, however, has been questioned in numerous studies (Battaglia et al., 1998; Bostick et al., 1998; Kruger et al., 1996; Wong et al., 1997; Wyld et al., 1998) . In general, the RT ± PCR based assays reveal nothing about the metastatic or clonogenic potential of the circulating tumor cells (Battaglia et al., 1998) . But in our study the detection of circulating emboli of MARY-X had signi®cance in that they were associated with increased numbers and sizes of pulmonary lymphovascular embolic metastases. The RT ± PCR demonstration of circulating tumor cells from passive metastasis in MARY-X would seem to correlate directly with clonogenic potential. Therefore the issue of the general signi®cance of circulating tumor cells may really depend on whether the circulating tumor cells are individual or present as intravascular emboli. When present as emboli they correlate with clonogenic potential because embolic dissemination is an ecient metastasis-generating mechanism and a mechanism which is characteristic of passive metastasis.
We realize that there are inherent limitations in extrapolating ®ndings made in human breast cancer xenograft model systems to breast cancers in humans. Still there are clinical situations in addition to IBC where LVI is conspicuous and the potential for passive metastasis a real concern. These include breast cancers of high Bloom Richardson grade, recurrent breast cancers occurring in mastectomy scars and locally advanced breast cancers which are status post neoadjuvant chemotherapy. All of these cancers exhibit a high degree of LVI and therefore the potential for passive metastasis.
Materials and methods

Establishment of MARY-X
MARY-X was established from a patient with IBC and exhibited the phenotype of¯orid local lymphovascular invasion (LVI) and¯orid local lymphovascular emboli formation in nude/scid mice (Alpaugh et al., 1999; Tomlinson et al., 2001) . MARY-X also spontaneously gave rise to low levels of pulmonary lymphovascular emboli. MARY-X was implanted into the ventrolateral¯anks of scid mice (Charles Rivers) and allowed to grow into 1.0 cm diameter tumors. MARY-X was also implanted into the mammary fat pads of the mice and allowed to grow in a similar manner. In MARY-X the murine component was considerable (30%). This murine component could be essentially eliminated by producing a MARY-X`shake' according to previous methods (Alpaugh et al., 1999; Tomlinson et al., 2001) . Thè shake' consisted of spheroids which grew in suspension culture.
Other cell lines and xenografts
The MCF-7, T47D, MDA-MB-231 and MDA-MB-468 lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD, USA), the C8161 and M24 met human melanoma lines were gifts of Dr Mary Hendrix (University of Iowa, Iowa City, IO, USA) and Dr Donald Morton (John Wayne Cancer Institute, Santa Monica, CA, USA). All lines were grown in MEM containing 10% fetal calf serum and antibiotics (100 units/ml penicillin and 100 mg/ ml streptomycin) at 378C in an air-5% CO 2 atmosphere at constant humidity. The MCF-7 and T47D lines were tumorigenic but non-metastatic in scid mice but required a 0.75 mg 17b-estradiol pellet (60 day release) for optimal tumorigenicity. The MDA-MB-231 and MDA-MB-468 lines were fully tumorigenic in the absence of estrogen, nonmetastatic over short incubation periods (4 ± 12 weeks) but lowly metastatic over longer incubation periods (12 ± 26 weeks). The C8161 and M24 met lines were highly metastatic over short incubation periods (4 ± 12 weeks) but metastasize as single cells . These latter lines did not, however, manifest LVI at the primary tumor site. Xenografts of these lines were generated by implantations of 1610 6 cells/ 200 l subcutaneously into either the ventrolateral¯anks or mammary fat pads of the mice and allowed to grow into 1.0 cm diameter tumors. We also used the malignant COLO-205 and COLO-201 lines (ATCC) as control because they overexpressed MUC-1 with sialyl-Lewis X/A residues, bound to endothelial cell E-selectin but did not manifest spontaneous metastasis. We also used human umbilical vein endothelial cells (HUVECs) (Clonetics, San Diego, CA, USA) to study attachment of selected tumor cell lines.
Antibodies
The antibodies used included monoclonal antibodies to Ecadherin (clone HECD-1) at a concentration of 1 ± 10 mg/ml (Zymed Laboratories, San Francisco, CA, USA); MUC-1, (clone HMPV, mouse IgG1) (PharMingen, San Diego, CA, USA) at a concentration of 1 ± 100 mg/ml; sialyl-Lewis X (sLeX) (clone CSLEX-1) and sialyl-Lewis A (sLeA) (clone CCOL-2) (UCLA Tissue Typing Laboratory, Los Angeles, CA, USA) each at concentrations of 10 mg/ml; cytokeratins 8, 18, 19 (DAKO, Carpinteria, CA, USA) at a concentration of 10 mg/ml; FITC-conjugated rat anti-mouse H-2K d (Seikagaku Co., Tokyo, Japan) at 1/10 ± 1/100 dilutions; b-actin, a gift of Dr Judy Berliner, UCLA at concentrations of 1 ± 10 mg/ml; and control murine IgG1 (DAKO, Glostrup, Denmark) at a concentration of 50 mg/ml.
Western analysis
The cell lines were harvested and immediately frozen. The xenografts were excised, frozen and pulverized with mortar and pestle to a ®ne powder. Both were then extracted with buer (1% Triton X-100, aprotinin (2 mg/ml), leupeptin (2 mg/ml), NaF (100 mM), sodium orthovanadate (2 mM), NaCl (150 mM), sodium phosphate (10 mM), EDTA (10 mM)) for 4 h at 48C with gentle agitation. The samples were then centrifuged at 13 000 g at 48C for 15 min. Protein concentrations were determined using the Bio Rad reagent (BioRad Laboratories, Hercules, CA, USA). Samples containing equal protein were boiled in a 16Leammli buer under reducing conditions, run on a 7.5% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane which was incubated with the primary and secondary antibodies and signal detected with the ECL detection system (Amersham Life Sciences, Arlington Heights, IL, USA). A monoclonal antibody to b-actin was used to normalize for protein loading. (Zhu and Watt, 1996) were used in conjunction with a packaging plasmid (1.2 pmol) (pCL-Ampho) (Imgenex, San Diego, CA, USA) (Naviaux et al., 1996) to transiently transfect 293T cells (10 6 cells) via a calcium phosphate transfection method as stated previously (Tomlinson et al., 2001) . Harvesting of the viral supernatants in conditioned media (Iscove's modi®ed Dulbecco's medium with 10% FCS) was begun at 36 h post transfection and collected every 4 ± 6 h up to 72 h. Twenty®ve ml of viral supernatant was ®lter sterilized through a 0.45 mm pore size ®lter and used in subsequent experiments. This approach produced high titres (10 6 ± 10 7 c.f.u./ml) of helper-free retrovirus containing the desired constructs. The dominant negative E-cadherin mutant (H-2K d -E-cad) encoded a 66 kDa chimeric protein consisting of the extracellular domain of H-2K d (297 amino acids) linked to the C terminal 191 amino acids of mouse E-cadherin, which comprised 16 amino acids of the extracellular domain and the entire transmembrane and cytoplasmic domains containing the catenin binding site. As a control a construct (H-2K
Retroviral transfection studies
d -E-cadD25) was derived from this dominant negative mutant in which the catenin binding site had been destroyed by a 25 amino acid deletion in the cytoplasmic domain (Zhu and Watt, 1996) . The ®ltered undiluted retroviral supernatants were used immediately in some experiments or aliquoted and stored at 7708 C for later use. A novel disadherence/ transfection/readherence strategy which allowed ecient gene transfer to all the cells of the MARY-X spheroids was used: 10 3 ± 10 4 spheroids of MARY-X (average size 100 ± 200 mm diameter) were disadhered in Ca 2+ free media under conditions previously established (Tomlinson et al., 2001) . Following complete disadherence which occurred after 30 min, the cells were plated onto 60 mm dishes in 2 ml of Ca 2+ -containing viral supernatant in the presence of polybrene (8 mg/ml) according to parameters previously de®ned (Fujiwara et al., 1993) . Infection was carried out in a humidi®ed incubator at 378C in an air ± 5% CO 2 atmo-sphere at constant humidity over 3 h. After this the viral supernatant was removed and the cells were placed in Ca 2+ -containing DMEM with 10% FCS. After 12 h, the disadhered transfected cells had undergone complete readherence into compact spheroids. Over the next 48 ± 96 h the spheroids were observed for gene expression and/or phenotypic changes. The presence of H-2K d (Noun et al., 1996) was determined by incubating the spheroids with the FITCconjugated rat anti mouse H-2K d monoclonal antibody at 1/ 10 ± 1/100 dilutions at room temperature for 1 ± 2 h followed by thorough washings. In some experiments the spheroids were permeabilized with absolute methanol for 20 min at 7208C prior to incubation with antibody. H-2K d expression was determined with an inverted Nikon¯uorescent microscope.
In vitro spheroid immunocytochemical and disadherence assays MARY-X spheroids were individually placed into wells of a 96-well plate containing 50 ml of media for immunocytochemical studies. Anti-E-cadherin antibody (1 ± 10 mg/ml), anti-MUC-1 (1 ± 100 mg/ml), anti-sLeX (10 mg/ml), anti-sLeA (10 mg/ml) and murine IgG1 (50 mg/ml) were separately added to dierent wells for parallel immunocytochemical studies. The presence of membrane immunoreactivity to Ecadherin, MUC1, sLeX and sLeA was determined with standard immunocytochemical (immunoperoxidase) protocols. The retrovirally transduced spheroids which were transfected with the dominant negative E-cadherin mutant (H-2K
d -E-cad) or its control (H-2K
d -E-cadD25) were monitored for disadherence by visualization under a phase contrast microscope at successive time points over 96 h.
In vitro HUVEC attachment assays
HUVECs were plated to form a monolayer on gelatinized 96-well culture plates at 20 000 cells/well and incubated at 378C in 5% CO 2 for 24 h. The cells were maintained in HUVEC growth medium that consisted of medium 199 (GIBCO ± BRL) with 10% heat-inactivated FCS. Selected wells were treated with 200 U/ml of tumor necrosis factor (TNF-a) (SIGMA, St. Louis, MO, USA), a known inducer of endothelial cell selectins (Bischo and Brasel, 1995) . A sensitive enzyme-linked immunosorbent assay (ELISA) (clone H18/7) (Becton Dickinson, San Jose, CA, USA) was used to measure the expression of E-selectin in both the treated and untreated HUVECs . MARY-X spheroids, the disadhered MARY-X dominant negative Ecadherin mutant (H-2K d -E-cad) and selected other cell lines were then plated at 10 000 cells (or spheroids) per well and incubated for 30 min at 48C. Unbound cells (or spheroids) were removed by aspiration and washing the plates with PBS containing CaCl 2 and MgCl 2 for ®ve times. The bound cells (or spheroids) were ®xed with methanol. Attachment was quantitated by counting cells under 6200 magni®cation using a Zeiss microscope.
Animal studies and studies of passive metastasis (palpation studies)
Female scid mice were used in all studies. The MARY-X spheroids which had been transfected ex vivo with the dominant negative E-cadherin mutant (H-2K
d -E-cad) and control (H-2K d -E-cadD25) were implanted into mice and their tumorigenicity and histopathology observed. Although we implanted the spheroids of MARY-X subcutaneously, we studied the spontaneous metastasis of the lymphovascular emboli of MARY-X. Studies of passive metastasis (palpation metastasis) were conducted with these groups and compared with native MARY-X, and the MCF-7, T47D, MDA-MB-231, MDA-MB-468, C8161 and M24 met xenografts. After implantation, the xenografts were allowed to grow to a diameter of 1.0 cm. Studies of the eects of palpation on passive metastasis were initiated only at that point. The tumoral xenografts therefore were well established and vascularized prior to palpation. Each mouse was grasped and held in the supine position and the tumor was palpated between the fore®nger and thumb (repeated 15 consecutive times). Palpation was conducted every third day over a two week period during which time the xenografts increased from 1.0 to 1.5 cm in diameter. At the end of the period of palpation, the xenografts were measured, extirpated and examined histologically. The lungs were removed, in¯ated, embedded, sectioned and stained with hematoxylin and eosin and a monoclonal antibody cocktail to cytokeratins 8, 18, 19. The presence, immunoreactivity, number and size of pulmonary lymphovascular emboli and/or metastatic colonies in mid-longitudinal cross-section of lung were determined. Results were tabulated with the assistance of digital image analysis and expressed as mean+standard error of the mean for 20 lungs (10 mice) in each group.
Monitoring of intratumoral pressure
Intratumor pressures were measured in selected mice (three from each group) using a 22 gauge needle introduced into the tumor parenchyma attached in series to a disposable Baxter PX260 transducer (Irvine, CA, USA), a Spacelabs Medical module ultraview 1600 and a Spacelabs Medical ultraview 1700 monitor. Five separate intratumoral pressure measurements (center and four quadrants) were made for each xenograft and the average pressure recorded. Intratumoral pressure measurements were recorded before, during and after palpation.
RT ± PCR studies
Based on our initial observations, selected xenografts (MARY-X, the MARY-X dominant negative E-cadherin mutant (H-2K d -E-cad), MDA-MB-231-X, C8161-X) were excised and immediately frozen in liquid nitrogen and pulverized with mortar and pestle to a ®ne powder and subjected to RNA extraction using Trizol reagent (Gibco ± BRL). RT ± PCR for human cytokeratin 19 (Battaglia et al., 1998) was initially performed on 30 ng of this extracted tumoral RNA to verify whether this gene was expressed at signi®cant levels in all of the dierent cell lines/xenografts being studied to make it a useful target. The cytokeratin 19 RT ± PCR was next performed on RNA extracted from varying numbers of human tumor cells (30 000?1) mixed with 300 l of murine blood to determine the sensitivity of this assay for detecting human tumor cells in a murine background. Finally the cytokeratin 19 RT ± PCR was performed on RNA extracted from murine blood obtained from the groups of palpated v non-palpated xenografts. 300 l blood was obtained from right heart puncture with a 22 gauge needle 2 ± 3 min after palpation of 1.5 cm sized xenografts. RNA was extracted with the Qiagen QIAamp RNA Blood Mini Kit (Qiagen, Inc., Valencia, CA, USA) according to the standard protocols provided in the kit. The RNA samples were further DNase I treated and RT ± PCR was carried out using Ready-To-Go 2 RT ± PCR Beads (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). We followed the single tube protocol for RT ± PCR (Battaglia et al., 1998) , using pd(T)12 ± 18 as the ®rst strand primer for reverse transcription. PCR was then carried out using two primers for human cytokeratin 19 which ampli®ed a 209 bp product: Sense primer (50 pmol): 5'-TGA ACC AGG CTT CAG CAT C-3' and antisense primer (50 pmol): 5'-GCA GAT CGA AGG CCT GAA-3'. RT ± PCR was carried out in 1 mM MgSO 4 with 200 mM dNTPs. Using a Perkins-Elmer Cetus DNA Thermal Cycler, the cDNA copy of the cytokeratin 19 sequence was created with 10 l Avian Myeloblastosis Virus Reverse Transcriptase (AMV) in 56 reaction buer by incubating the samples at 428C for 27 min, then 5 min at 958C to deactivate the AMV, then 48C at which time the cytokeratin 19 sense and antisense primers were added together with 5 U Thermus¯avus DNA Polymerase (T¯). Next, the PCR program was carried out as follows: 948C for 30 s, 588C for 1 min, 688C for 2 min (30 cycles) and 7 min at 688C (one cycle). The RT ± PCR products (15 l) were separated on a 2% agarose gel at 80 V for 1 h, then stained with ethidium bromide and photographed with the Gel Doc 1000 System and Software (BioRad).
ELISA studies
We then examined murine serum of palpated v non-palpated MARY-X for levels of the following factors: IGF-I, IGF-II, TGF-a, TGF-b, VEGF and bFGF. We used the quantitative sandwich enzyme immunoassay (ELISA) for VEGF, bFGF, IGF-I and TGF-b (R&D Systems, Minneapolis, MN, USA). We used a modi®ed ELISA for IGF-II (PeproTech, Inc., Rocky Hill, NJ, USA) and TGF-a (Oncogene Research Products, Cambridge, MA, USA). These assays could detect circulating human growth and angiogenic factors in murine serum to levels as low as 5 ± 25 pg/ml. 300 l blood was obtained from right heart puncture 2 ± 3 min after palpation. A serum separator tube allowed samples to clot for 30 min prior to centrifugation for 10 min at 1000 g. Serum samples were assayed immediately.
Studies of human IBC cases
Twenty-®ve cases of IBC previously retrieved and used in prior studies (Alpaugh et al., 1999; Tomlinson et al., 2001) were studied immunocytochemically with standard immunoperoxidase protocols using antibodies to MUC1, sLeX, sLeA, and control murine IgG1. Non-IBC and normal breast tissues were used as controls.
Statistical analysis
Experiments were performed with groups of 10 mice and results analysed with standard tests of signi®cance, including the two-tailed Student's t-test and a one-way analysis of variance (ANOVA).
Institutional certifications
Informed patient consent and approvals from the UCLA Human Subject Protection Committee, the Chancellor's Animal Research Committee (certi®cation ARC 95-127-11), and the UCLA Institutional Biosafety Committee (IBC) were obtained prior to all studies.
